The pharmacological effect of BGC20-1531, a novel prostanoid EP 4 receptor antagonist, in the Prostaglandin E 2 human model of headache

Journal of Headache and Pain

Volumn 12, Issue 5, 2011, Pages 551-559

  Antonova, Maria ^a   Wienecke, Troels ^a   Maubach, Karen ^b   Thomas, Emma ^b   Olesen, Jes ^a   Ashina, Messoud ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b BTG   (United Kingdom)

Author keywords

BGC20 1531; EP 4 receptor antagonist; Headache; Prostaglandin E 2; Vasodilatation

Indexed keywords

BGC 201531; PLACEBO; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; BLOOD FLOW VELOCITY; CHEST TIGHTNESS; CHILL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG POTENCY; FEMALE; FLUSHING; HEADACHE; HEART PALPITATION; HEAT SENSATION; HUMAN; INJECTION SITE IRRITATION; LOW BACK PAIN; MALE; MIDDLE CEREBRAL ARTERY; MUCUS SECRETION; MUSCLE STIFFNESS; NAUSEA; NORMAL HUMAN; PAIN ASSESSMENT; PARESTHESIA; PHONOPHOBIA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SINGLE DRUG DOSE; SUPERFICIAL TEMPORAL ARTERY; THIRST; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; VASODILATATION;

ADULT; ANALGESICS; CEREBROVASCULAR CIRCULATION; CROSS-OVER STUDIES; DINOPROSTONE; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; MALE; PYRIDINES; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SULFONAMIDES; VASODILATION; YOUNG ADULT;

EID: 80054022565     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-011-0358-9     Document Type: Article

References (41)

1. X Norel 2007 Prostanoid receptors in the human vascular wall Sci World J 7 1359 1374 1:CAS:528:DC%2BD2sXhtlequ77J (Pubitemid 47435435)
2. M Bianchi C Martucci P Ferrario S Franchi P Sacerdote 2007 Increased tumor necrosis factor-alpha and prostaglandin E2 concentrations in the cerebrospinal fluid of rats with inflammatory hyperalgesia: the effects of analgesic drugs Anesth Analg 104 949 954 17377112 10.1213/01.ane.0000258060. 89380.27 1:CAS:528:DC%2BD2sXjvVKis78%3D (Pubitemid 46548327)
3. RA Coleman WL Smith S Narumiya 1994 International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes Pharmacol Rev 46 205 229 7938166 1:CAS:528:DyaK2cXlslSlsbo%3D (Pubitemid 24185151)
4. V Jadhav A Jabre SZ Lin TJ Lee 2004 EP1- and EP3-receptors mediate prostaglandin E2-induced constriction of porcine large cerebral arteries J Cereb Blood Flow Metab 24 1305 1316 15625406 10.1097/01.WCB.0000139446.61789.14 1:CAS:528:DC%2BD2MXjtFyg (Pubitemid 40019155)
5. M Negishi Y Sugimoto A Ichikawa 1995 Molecular mechanisms of diverse actions of prostanoid receptors Biochim Biophys Acta 1259 109 119 7492609
6. RJ Davis CE Murdoch M Ali S Purbrick R Ravid GS Baxter, et al. 2004 EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries Br J Pharmacol 141 580 585 14744815 10.1038/sj.bjp.0705645 1:CAS:528: DC%2BD2cXivVCmtbo%3D (Pubitemid 38453250)
7. CA Kassuya J Ferreira RF Claudino JB Calixto 2007 Intraplantar PGE2 causes nociceptive behaviour and mechanical allodynia: the role of prostanoid E receptors and protein kinases Br J Pharmacol 150 727 737 17310141 10.1038/sj.bjp.0707149 1:CAS:528:DC%2BD2sXjtFCqtL0%3D (Pubitemid 46440219)
8. JA Smith CL Davis GM Burgess 2000 Prostaglandin E2-induced sensitization of bradykinin-evoked responses in rat dorsal root ganglion neurons is mediated by cAMP-dependent protein kinase A Eur J Neurosci 12 3250 3258 10.1046/j.1460-9568.2000.00218.x 1:STN:280:DC%2BD3M%2FhslWgsQ%3D%3D
9. CR Lin F Amaya L Barrett H Wang J Takada TA Samad, et al. 2006 Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity J Pharmacol Exp Ther 319 1096 2103 16966471 10.1124/jpet.106.105569 1:CAS:528:DC%2BD28Xht1yltL%2FP
10. MD Southall MR Vasko 2001 Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons J Biol Chem 276 16083 16091 11278900 10.1074/jbc.M011408200 1:CAS:528:DC%2BD3MXjvFakt70%3D
11. K Nakao A Murase H Ohshiro T Okumura K Taniguchi Y Murata, et al. 2007 CJ-023, 423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties J Pharmacol Exp Ther 322 686 694 17495127 10.1124/jpet.107.122010 1:CAS:528:DC%2BD2sXoslSjtbc%3D (Pubitemid 47105812)
12. KA Maubach RJ Davis DE Clark G Fenton PM Lockey KL Clark, et al. 2009 BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache Br J Pharmacol 156 316 327 19154437 10.1111/j.1476-5381.2009.00027.x 1:CAS:528:DC%2BD1MXpt1Wlsr4%3D
13. T Wienecke J Olesen PS Oturai M Ashina 2009 Prostaglandin E2(PGE2) induces headache in healthy subjects Cephalalgia 29 509 519 19187340 10.1111/j.1468-2982.2008.01748.x 1:STN:280:DC%2BD1M3oslamtg%3D%3D
14. HK Iversen J Olesen P Tfelt-Hansen 1989 Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics Pain 38 17 24 2506503 10.1016/0304-3959(89)90067-5 1:CAS:528:DyaL1MXltlWru7o%3D (Pubitemid 19184833)
15. J Olesen TJ Steiner 2004 The International classification of headache disorders, 2nd edn (ICDH-II) J Neurol Neurosurg Psychiatry 75 808 811 15145989 10.1136/jnnp.2003.031286 1:STN:280:DC%2BD2c3kslGnuw%3D%3D (Pubitemid 38658498)
16. LL Thomsen HK Iversen 1993 Experimental and biological variation of three-dimensional transcranial Doppler measurements J Appl Physiol 75 2805 2810 7907324 1:STN:280:DyaK2c7ntFKquw%3D%3D (Pubitemid 24008404)
17. JN Matthews DG Altman MJ Campbell P Royston 1990 Analysis of serial measurements in medical research BMJ 300 230 235 2106931 10.1136/bmj.300.6719. 230 1:STN:280:DyaK3c7otFKqsg%3D%3D (Pubitemid 20045528)
18. Altman DG (1999) Practical statistics for medical research. Chapman & Hall, London, pp 455-458
19. Busija D (2002) Prostaglandins and other Eicosanoids 2. In: Edvinsson L, Krause DN (eds) Cerebral blood flow and metabolism, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 325-338
20. M Myren M Baun BK Ploug I Jansen-Olesen S Gupta 2010 Functional and molecular characterization of prostaglandin E2 dilatory receptors in the rat craniovascular system in relevance to migraine Cephalalgia 30 1110 1122 20713561 10.1177/0333102409357957
21. ET Whalley L Schilling M Wahl 1989 Cerebrovascular effects of prostanoids: in-vitro studies in feline middle cerebral and basilar artery Prostaglandins 38 625 634 2483755 10.1016/0090-6980(89)90045-2 1:CAS:528:DyaK3cXntVOksQ%3D%3D (Pubitemid 20026279)
22. M Wahl L Schilling ET Whalley 1989 Cerebrovascular effects of prostanoids. In-situ studies in pial arteries of the cat Naunyn Schmiedebergs Arch Pharmacol 340 314 320 2812043 10.1007/BF00168516 1:CAS:528: DyaL1MXmt1Gru70%3D (Pubitemid 19240123)
23. WM Armstead 1995 Role of nitric oxide and cAMP in prostaglandin-induced pial arterial vasodilation Am J Physiol 268 H1436 H1440 7733344 1:CAS:528:DyaK2MXlt1GjtL0%3D
24. LF Donaldson PS Humphrey S Oldfield S Giblett BD Grubb 2001 Expression and regulation of prostaglandin E receptor subtype mRNAs in rat sensory ganglia and spinal cord in response to peripheral inflammation Prostaglandins Other Lipid Mediat 63 109 122 11204738 10.1016/S0090-6980(00)00101-5 1:CAS:528:DC%2BD3MXms1Wgtw%3D%3D (Pubitemid 32332990)
25. H Oida T Namba Y Sugimoto F Ushikubi H Ohishi A Ichikawa, et al. 1995 In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs Br J Pharmacol 116 2828 2837 8680713 1:CAS:528:DyaK2MXpslOhurw%3D
26. T Kumazawa K Mizumura H Koda 1993 Involvement of EP3 subtype of prostaglandin E receptors in PGE2-induced enhancement of the bradykinin response of nociceptors Brain Res 632 321 324 8149238 10.1016/0006-8993(93)91169-S 1:CAS:528:DyaK2cXntVWhtg%3D%3D (Pubitemid 24015533)
27. T Moriyama T Higashi K Togashi T Iida E Segi Y Sugimoto, et al. 2005 Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins Mol Pain 1 3 15813989 10.1186/1744-8069-1-3 (Pubitemid 44848619)
28. T Oka S Aou T Hori 1994 Intracerebroventricular injection of prostaglandin E2 induces thermal hyperalgesia in rats: the possible involvement of EP3 receptors Brain Res 663 287 292 7874513 10.1016/0006-8993(94)91275-0 1:CAS:528:DyaK2cXmvFemtr0%3D (Pubitemid 24339044)
29. A Hall SH Brown C Budd NM Clayton GM Giblin P Goldsmith, et al. 2009 Discovery of GSK345931A: an EP(1) receptor antagonist with efficacy in preclinical models of inflammatory pain Bioorg Med Chem Lett 19 497 501 19036582 10.1016/j.bmcl.2008.11.032 1:CAS:528:DC%2BD1MXmt1aj
30. L Popp A Haussler A Olliges R Nusing S Narumiya G Geisslinger, et al. 2009 Comparison of nociceptive behavior in prostaglandin E, F, D, prostacyclin and thromboxane receptor knockout mice Eur J Pain 13 691 703 18938093 10.1016/j.ejpain.2008.09.001 1:CAS:528:DC%2BD1MXnslyqtLw%3D
31. J Olesen HC Diener IW Husstedt PJ Goadsby D Hall U Meier, et al. 2004 Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine N Engl J Med 350 1104 1110 15014183 10.1056/NEJMoa030505 1:CAS:528:DC%2BD2cXitV2qur0%3D (Pubitemid 38298990)
32. S Narumiya Y Sugimoto F Ushikubi 1999 Prostanoid receptors: structures, properties, and functions Physiol Rev 79 1193 1226 10508233 1:CAS:528: DyaK1MXmvVymtL0%3D (Pubitemid 29473315)
33. N Foudi L Kotelevets L Louedec G Leseche D Henin E Chastre, et al. 2008 Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype Br J Pharmacol 154 1631 1639 18516068 10.1038/bjp.2008.214 1:CAS:528:DC%2BD1cXps1Gru70%3D
34. KL Therland J Stubbe HC Thiesson PD Ottosen S Walter GL Sorensen, et al. 2004 Cycloxygenase-2 is expressed in vasculature of normal and ischemic adult human kidney and is colocalized with vascular prostaglandin E2 EP4 receptors J Am Soc Nephrol 15 1189 1198 15100359 10.1097/01.ASN.0000124673.79934.24 1:CAS:528:DC%2BD2cXjtVCnurY%3D (Pubitemid 38526000)
35. M Bastepe B Ashby 1997 The long cytoplasmic carboxyl terminus of the prostaglandin E2 receptor EP4 subtype is essential for agonist-induced desensitization Mol Pharmacol 51 343 349 9203641 1:CAS:528:DyaK2sXhtlWmsLY%3D (Pubitemid 27074157)
36. A Ichikawa Y Sugimoto M Negishi 1996 Molecular aspects of the structures and functions of the prostaglandin E receptors J Lipid Mediat Cell Signal 14 83 87 8906549 10.1016/0929-7855(96)00512-3 1:CAS:528:DyaK28XlvFGgtL0%3D (Pubitemid 26343341)
37. JW Regan 2003 EP2 and EP4 prostanoid receptor signaling Life Sci 74 143 153 14607241 10.1016/j.lfs.2003.09.031 1:CAS:528:DC%2BD3sXos12qtro%3D (Pubitemid 37357046)
38. S Desai H April C Nwaneshiudu B Ashby 2000 Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration Mol Pharmacol 58 1279 1286 11093764 1:CAS:528:DC%2BD3cXovFeqsrw%3D
39. N Nishigaki M Negishi A Ichikawa 1996 Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist Mol Pharmacol 50 1031 1037 8863851 1:CAS:528:DyaK28XmsFGnsr8%3D (Pubitemid 26347726)
40. HH Tai CM Ensor M Tong H Zhou F Yan 2002 Prostaglandin catabolizing enzymes Prostaglandins Other Lipid Mediat 68-69 483 493 12432938 10.1016/S0090-6980(02)00050-3 (Pubitemid 35247416)
41. KA Petersen LH Lassen S Birk L Lesko J Olesen 2005 BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation Clin Pharmacol Ther 77 202 213 15735614 10.1016/j.clpt.2004. 10.001 1:CAS:528:DC%2BD2MXhsVyrs7Y%3D (Pubitemid 40269135)